The Start-ups Meet Pharma is a challenge-based acceleration program focused on selecting the most promising health start-ups and scale-ups matching the corporate partners’ innovation needs, to deliver solutions that address quality and affordable healthcare for European patients. In 2022, we are enabling unparalleled exposure to industry executives and decision-makers at Novartis, Boehringer Ingelheim, Sintetica and Takeda through one-to-one pitch sessions, support, value proposition development and partnership exploration.
If you are developing innovative technologies and services representing potential solutions for the selected challenges for 2022, submit your application now!
The global prevalence of Chronic Kidney disease is around 9% and is often underrecognized by patients and clinicians. Diagnosis, staging and appropriate referral of CKD patients by primary care physicians are important elements in reducing the burden of the disease. Boehringer Ingelheim is looking for a digital diagnostic support tool that aids the diagnosis of new CKD patients; flags the unrecognized CKD patients – especially those with high risk for progression; and could be integrated with the daily workflow of GPs.
People living with rare diseases are often faced with challenges to obtain a correct diagnosis, and hence treatment. Takeda calls for digital health solutions that could improve or optimize the care and referral pathway for people with rare diseases to gain access to relevant laboratory testing to enable diagnosis and treatment decisions. There is a particular interest for solutions that could be applied to improve testing for Thrombotic thrombocytopenic purpura (TTP), which is an ultra-rare, life-threatening blood disorder.
Sintetica is looking for innovative solutions in pain management, related to chronic pain but also to pain treatment in general, that could improve patients’ lives. These solutions could include but are not limited to: new types of pharmacological treatment, novel drug delivery routes, medical devices, digital approaches. There is a particular interest in the field of neuromodulation which is an expanding area of pain medicine that incorporates an array of non-invasive, minimally invasive, and surgical electrical therapies.
Novartis is looking for a proven solution or platform that can support integrated care pathway (screening & diagnosis / identify patient, automate referral, treatment activation and follow-up) including any digital health interventions (e.g., behavior change / psychosocial aid/adherence) to optimize patient outcome (QoL, morbidity/mortality, productivity), reduce disease burden and minimize avoidable human resource utilization.